A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 (ASTRID – Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics).

Registry ID

EUCTR2004-000703-18

Source registry

EUCTR

Status

Ongoing

Phase

PHASE3

Sponsor

SOLVAY PHARMACEUTICALS GMBH

Start date

2004-10-27

Last update

2026-08-16

Conditions

• Essential hypertension with associated Diabetes Mellitus type 2.
• essential hypertension

Summary

To demonstrate the superiority of combination therapy of Eprosartan/HCTZ (600/12.5 mg) versus Ramipril/HCTZ (5/12.5 mg) in terms of proportion of patients brought to goal blood pressure (< 130/80 mmHg) at V3 vs. V2 (after four weeks of treatment).

Locations

• , , Italy
• , , Spain

View on source registry